Drug Profile
M3
Latest Information Update: 29 Jul 2004
Price :
$50
*
At a glance
- Originator Xenova Group
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 29 Jul 2004 Discontinued - Preclinical for Autoimmune disorders in United Kingdom (unspecified route)
- 29 Jul 2004 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
- 29 Jul 2004 Discontinued - Preclinical for Inflammation in United Kingdom (unspecified route)